Gold is 2025’s best performer. UBS sees more upside
Investing.com -- Inspire Medical (TASE:BLWV) Systems, Inc. (NYSE:INSP) reported better-than-expected first quarter results and raised its full-year earnings guidance, sending shares up 1.5% in after-hours trading.
The sleep apnea device maker posted adjusted earnings per share of $0.10 for Q1 2025, surpassing analyst estimates of a $0.24 loss. Revenue grew 23% YoY to $201.3 million, exceeding the consensus forecast of $195.2 million.
Inspire’s U.S. revenue jumped 24% to $193.6 million, while international sales dipped 6% to $7.7 million. The company achieved a gross margin of 84.7% for the quarter.
"We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability," said Tim Herbert, Chairman and CEO of Inspire Medical Systems. "We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption."
For the full year 2025, Inspire maintained its revenue guidance of $940-955 million but raised its EPS outlook to $2.20-$2.30, up from $2.10-$2.20 previously. The new EPS guidance tops the analyst consensus of $2.16.
The company ended the quarter with $414.0 million in cash and investments, down from $516.5 million at the end of 2024.
Inspire’s operating loss narrowed to $1.5 million from $15.2 million a year ago, reflecting improved operating leverage as revenue growth outpaced the 11% rise in operating expenses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.